Published in Cell Death Dis on June 20, 2013
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | NCT01449279
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget (2015) 0.96
Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. Oncotarget (2014) 0.94
Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res (2015) 0.86
Harnessing the immune system to improve cancer therapy. Ann Transl Med (2016) 0.83
The redox biology network in cancer pathophysiology and therapeutics. Redox Biol (2015) 0.83
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer (2014) 0.82
Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol (2014) 0.80
Implication of transcriptional repression in compound C-induced apoptosis in cancer cells. Cell Death Dis (2013) 0.79
Protecting the normal in order to better kill the cancer. Cancer Med (2015) 0.78
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One (2016) 0.78
Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res (2015) 0.78
Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer (2015) 0.78
Extracellular Vesicles Mediate Radiation-Induced Systemic Bystander Signals in the Bone Marrow and Spleen. Front Immunol (2017) 0.76
ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. Fukushima J Med Sci (2015) 0.76
Potential role of High mobility group box 1 in hepatocellular carcinoma. Cell Adh Migr (2014) 0.75
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer (2002) 5.87
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 5.65
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol (2006) 2.90
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut (1998) 2.11
HMGB1 as a DNA-binding cytokine. J Leukoc Biol (2002) 2.07
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol (2006) 1.74
An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol (1975) 1.72
Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med (1999) 1.71
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
New roles for TIM family members in immune regulation. Nat Rev Immunol (2008) 1.68
Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol (2008) 1.66
Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 1.62
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg (1995) 1.54
The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol (2006) 1.53
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med (2009) 1.51
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci (2009) 1.49
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. Ann Thorac Surg (2005) 1.40
Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res (2012) 1.40
The abscopal effect: demonstration in lymphomatous involvement of kidneys. Med Pediatr Oncol (1981) 1.40
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
ERp57 and PDI: multifunctional protein disulfide isomerases with similar domain architectures but differing substrate-partner associations. Biochem Cell Biol (2006) 1.30
Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol (1999) 1.24
The immunogenicity of tumor cell death. Curr Opin Oncol (2009) 1.19
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology (2012) 1.16
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology (2012) 1.12
Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci (2008) 1.11
Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer (2010) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol (2012) 1.04
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 1.00
Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci (2012) 0.97
Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One (2012) 0.97
HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol (2012) 0.96
HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol (2012) 0.92
Regulatory T cells in γ irradiation-induced immune suppression. PLoS One (2012) 0.91
Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res (2011) 0.88
Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. Nutrition (2001) 0.83
Radiosensitivity of human squamous carcinoma cell lines is associated with amount of spontaneous DNA strand breaks. Int J Cancer (2001) 0.76
Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment. Oncoimmunology (2012) 0.76
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev (1979) 3.15
The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood (2000) 3.09
Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol (1977) 3.05
Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature (1977) 2.39
Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol (1978) 2.29
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
Observation of the one-dimensional diffusion of nanometer-sized dislocation loops. Science (2007) 2.07
The recombinant 65-kD heat shock protein of Mycobacterium bovis Bacillus Calmette-Guerin/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes. J Exp Med (1988) 2.04
Natural killer cells in the mouse: an alternative immune surveillance mechanism? Contemp Top Immunobiol (1978) 1.96
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Target--effector interaction in the natural killer cell system. I. Covariance and genetic control of cytolytic and target-cell-binding subpopulations in the mouse. Scand J Immunol (1978) 1.70
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol (1990) 1.51
Human fetal thymus and bone marrow contain target cells for natural killer cells. Eur J Immunol (1981) 1.51
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol (1985) 1.51
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med (1998) 1.50
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature (1980) 1.42
The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med (1989) 1.39
Natural killer cells. Prog Allergy (1981) 1.38
Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A (1992) 1.31
Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol (1982) 1.30
Natural NK-cell targets in the mouse thymus: characteristics of the sensitive cell population. J Immunol (1979) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension (2000) 1.29
T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components. Eur J Immunol (1989) 1.28
Presence of human 65 kD heat shock protein (hsp) in inflamed joints and subcutaneous nodules of RA patients. Scand J Immunol (1990) 1.27
Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis (1990) 1.23
NK cell-sensitive T-cell subpopulation in thymus: inverse correlation to host NK activity. Nature (1979) 1.20
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20
Generation of natural killer cells: an autonomous function of the bone marrow. J Exp Med (1977) 1.19
Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer (1975) 1.18
Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. Eur J Immunol (1990) 1.18
Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer (1995) 1.17
Target-effector cell interaction in the natural killer cell system. V. Energy requirements, membrane integrity, and the possible involvement of lysosomal enzymes. Immunology (1980) 1.15
A functional comparison of tumor cell killing by activated macrophages and natural killer cells. Eur J Immunol (1979) 1.12
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res (2001) 1.12
Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol (1999) 1.10
Activation of proteases in cerulein-induced pancreatitis. Pancreas (1989) 1.09
Cellular, humoral, and gamma interferon responses to Mycobacterium leprae and BCG antigens in healthy individuals exposed to leprosy. Scand J Immunol (1988) 1.08
Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res (1996) 1.08
Mycobacterial-induced cytotoxic T cells as well as nonspecific killer cells derived from healthy individuals and leprosy patients. Eur J Immunol (1990) 1.07
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother (2011) 1.07
Fly photoreceptors. II. Spectral and polarized light sensitivity in the drone fly Eristalis. Proc R Soc Lond B Biol Sci (1975) 1.06
NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol (1999) 1.06
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer (2007) 1.05
Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A (1987) 1.03
Improving the efficacy of cancer immunotherapy. Eur J Cancer (2009) 1.01
Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J Natl Cancer Inst (1978) 1.01
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer (2000) 1.00
Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer (2002) 1.00
Recovery of muscle power after high-intensity short-term exercise: comparing boys and men. J Appl Physiol (1985) (1993) 0.99
T cell receptor diversity and activation markers in the V delta 1 subset of rheumatoid synovial fluid and peripheral blood T lymphocytes. Eur J Immunol (1992) 0.99
A comparative analysis of the cell surface properties of activated vs endogenous mouse natural killer cells. J Immunol (1980) 0.99
Intra- and interspecies reactivity of human and mouse natural killer (NK) cells. J Immunol (1978) 0.98
In vivo function of natural killer cells as regulators of myeloid precursor cells in the spleen. Eur J Immunol (1988) 0.98
Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res (1999) 0.98
Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol (2001) 0.97
Correlation of glycosphingolipids and sialic acid in YAC-1 lymphoma variants with their sensitivity to natural killer-cell-mediated lysis. Int J Cancer (1981) 0.97
Mechanisms of lymphocytic choriomeningitis virus-induced hemopoietic dysfunction. J Virol (1986) 0.96
T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol (2000) 0.96
Induction of human hsp60 expression in monocytic cell lines. Int Immunol (1992) 0.96
Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients. Eur J Immunol (1992) 0.95
Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci (2001) 0.95
Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol (1993) 0.95
Variants from a MLV-induced lymphoma selected for decreased sensitivity to NK lysis. J Immunol (1981) 0.95
Decreased expression of signal-transducing CD3 zeta chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol (1998) 0.95
Mouse natural killer (NK) cell activity against human cell lines is not influenced by superinfection of the target cell with xenotropic murine C-type virus. Int J Cancer (1978) 0.94
Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension (1997) 0.94
Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol (2001) 0.94
Analysis of gamma delta V region usage in normal and diseased human intestinal biopsies and peripheral blood by polymerase chain reaction (PCR) and flow cytometry. Clin Exp Immunol (1995) 0.94
CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus (2009) 0.94
An immunofluorescent method for identifying individual IFN-gamma-producing lymphocytes. J Immunol Methods (1986) 0.93
Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases. J Immunol (1996) 0.93
Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol (1997) 0.93
In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige//nude and wild-type hosts on C57BL background. Int J Cancer (1980) 0.93
Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer (1998) 0.93
In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. Cell Immunol (1991) 0.92
Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci U S A (1997) 0.91
Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells. Int J Cancer (1991) 0.91
Hydroxyl radical formation by UV-irradiated epidermal cells. J Biochem (1992) 0.91
NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus (2010) 0.91
Gamma-interferon (IFN-gamma) produced during effector and target interactions renders target cells less susceptible to NK-cell-mediated lysis. Int J Cancer (1983) 0.91
The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. Eur J Immunol (2001) 0.91
Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J Intern Med (2014) 0.91
Her-2/neu as a paradigm of a tumor-specific target for therapy. Breast Dis (2004) 0.90
Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer (2011) 0.90
Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma delta subtype uncommon in peripheral blood. Scand J Immunol (1990) 0.90
Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. Int J Cancer (2012) 0.90
The value of a direct agglutination test in the diagnosis of cutaneous and visceral leishmaniasis in Ethiopia. Trans R Soc Trop Med Hyg (1991) 0.90
Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother (1993) 0.89
Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer (2009) 0.89
Minimum enzyme unit for Na+/K+-ATPase is the alpha beta-protomer. Determination by low-angle laser light scattering photometry coupled with high-performance gel chromatography for substantially simultaneous measurement of ATPase activity and molecular weight. Biochim Biophys Acta (1989) 0.89